Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024 published by Global Data now available at Zursh

San Diego: Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC).

In 2010, an estimated 786,000 HBV-related deaths occurred worldwide. Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance. 

The chronic hepatitis B therapeutics market in the 5EU was valued at $532.1m in 2014. The anticipated arrival of novel branded therapies will be the strongest market driver in the 5EU during the forecast period.
These therapies include Gilead's TAF, a novel NA, along with three adjunct therapies, Arrowhead's ARC-520, Gilead's GS-9620, and Gilead's GS-4774. GlobalData projects these four products will receive licensure in the 5EU in 2017, 2021, 2021, and 2023, respectively.

Scope

- Overview of HBV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU, including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU HBV market.

Key Topics Covered:

1. Tables & Figures
2 Introduction
2.1 Catalyst]
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.2 5EU
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
5.3 Other Therapeutics
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
6.4 Increased Access to Treatment
6.5 Drugs That Effectively Target and Suppress HBV cccDNA
6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients
6.7 Overcome Unique Barriers Posed by China's Healthcare System
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.3 Promising Drugs in Clinical Development
7.4 Other Drugs in Development
8 Market Outlook
8.1 5EU
9 Appendix

Please find more about Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024 at reports.zursh.com

Click on below items to see free updates about the topic covered.

Industry Updates

Click on below items to see free resources and reports about the topic covered.

Free Resources

Contact Information

Simon Sliman
Simon Sliman (write to Simon)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com
Lloyd Chambers
Lloyd Chambers (write to Lloyd)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

*We Don't Spam